September 11th, 2026

Company Name:	GENOVA Inc.
Representative:	President and Representative Director, Tomoki Hirase
(Ticker: 9341:	Tokyo Stock Exchange Prime Market)
Inquiries:	Board Director and Executive Officer, Koji Takeda

Notice Regarding the Acquisition of a Business

GENOVA Inc. (Representative Director: Tomoki Hirase; hereinafter, the "Company") hereby announces that, at a meeting of its Board of Directors held on September 11, 2026, a resolution was passed to acquire the "Karada ni Iikoto" business from Central Medience Co., Ltd. (Representative Director: Ryutaro Nakagawa; hereinafter "Central Medience") as described below.

The Company believes that the acquisition of this business will generate significant synergies with its Group's Medical Platform Business and will substantially contribute to the further expansion of the Medical Platform Business and the enhancement of corporate value.

Although this matter falls under the "minor" category of the Tokyo Stock Exchange's Timely Disclosure Rules, the Company has determined that it constitutes useful information for investors and has therefore decided to make a voluntary disclosure.

1. Reasons for the Business Acquisition

The Company is a healthcare technology company that provides services under its mission of "Creating a Healthier Society by Connecting People and Medical Care". The Company is committed to addressing the social challenges facing Japan, including the shortage of healthcare professionals resulting from the country's declining birthrate and aging population, as well as the need to extend healthy life expectancy and ensure appropriate access to healthcare amid the increasing burden of national healthcare expenditures. Through the services we provide, we seek to address the concerns and dissatisfaction of patients and users regarding their healthcare and well-being, while working to create a healthcare environment in which everyone can feel secure and confident in accessing the care they need.

The Company has decided to acquire the "Karada ni Iikoto" business operated by Central Medience. The business has earned strong and longstanding support from its readership and has established a strong track record in delivering high-quality healthcare content. Through the acquisition of this business, the Company expects to further strengthen its editorial capabilities within its media business by leveraging the extensive expertise and resources that "Karada ni Iikoto" has cultivated over the years. Furthermore, by acquiring publishing expertise through inhouse production of publishing media, we can build a diverse range of information distribution channels that extend beyond the online sphere to include offline media (such as printed publications).

Through these initiatives, the Company believes that it will be able to deliver high-quality healthcare information to an even broader audience, thereby strongly advancing the realization of our mission, "Creating a Healthier Society by Connecting People and Medical Care". Based on this conviction, the Company has decided to acquire this business.

2. Overview of the Business Acquisition

(1) Details of the Business to Be Acquired

Contracted editorial services, sponsored content and PR services built around the healthcare media platform "Karada ni Iikoto"

(2) Financial Results of the Business to Be Acquired

	Business to Be Acquired (Fiscal Year Ended April 30, 2026)
Sales	188 million yen

(3) Items and Amounts of Assets and Liabilities of the Business to Be Acquired

The Company will acquire only the assets associated with the business being acquired. Items relating to the assets and liabilities to be acquired that are immaterial in amount have been omitted.

(4) Acquisition Price and Settlement Method

(a) Acquisition price: 51 million yen (expected)

(b) Settlement method: Cash settlement

3. Overview of the Counterparty

(1)	Name	Central Medience Co., Ltd.	
(2)	Address	8th Floor, Shinagawa Grand Central Tower 2-16-4 Konan, Minato-ku, Tokyo, Japan	
(3)	Title and Name of Representative	Ryutaro Nakagawa, Representative Director	
(4)	Business Description	Medical Testing, Medical Consulting, and Related Services	
(5)	Capital	100 million yen	
(6)	Date of Establishment	May 16, 2018	
(7)	Net Assets	15 million yen	
(8)	Total Assets	1,035 million yen	
(9)	Major Shareholders and Shareholding Ratios	Coriva Partners Co., Ltd. 66.9% Ryutaro Nakagawa 27.7%	
(10)	Relationship between the Listed Company and the Company	Capital Relationship	Not applicable
		Personnel Relationship	Not applicable
		Business Relationship	Not applicable
		Status of Related Parties	Not applicable

4. Scheduled Dates

Date of Resolution by the Board of Directors of the Company	September 11, 2026
Contract Date	September 14, 2026
Business Transfer Date	September 14, 2026 (scheduled)

5. Overview of Accounting Procedures

The acquisition of this business is expected to constitute an "acquisition" under the Accounting Standard for Business Combinations. The amount of goodwill and other intangible assets to be recognized in connection with this transaction, as well as their amortization periods and other related matters, are currently under review.

6. Outlook

Although the impact of this matter on our financial results for the fiscal year ending March 2027 will be minor, prompt notification will be provided should any impact requiring disclosure arise in the future.